```html

Zollinger–Ellison Syndrome (Recurrent Ulcer Disease) – A Comprehensive Medical Guide

Overview

Zollinger–Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (known as gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, leading to hyper‑acidic gastric secretions. The resulting acid overload overwhelms the protective mechanisms of the upper gastrointestinal (GI) tract, causing recurrent, often severe peptic ulcers that may appear in atypical locations such as the jejunum or even the distal small bowel.

Although ZES accounts for less than 1 % of all peptic ulcer disease, it is clinically important because the ulcers are refractory to standard therapy and may signal an underlying neuroendocrine tumor that can be malignant.

• Age: Most patients are diagnosed between 30 and 60 years; a smaller peak occurs in patients under 20 (often hereditary).
• Sex: Slight male predominance (≈55 % male).
• Prevalence: Estimated 1–3 cases per million population worldwide (≈0.1 % of all gastric ulcers).<sup>1</sup>
• Genetics: About 20‑30 % are linked to hereditary multiple endocrine neoplasia type 1 (MEN‑1) syndrome.

Symptoms

Because the hallmark of ZES is relentless gastric acid secretion, symptoms are primarily related to ulcer disease and acid‑related injury. The presentation can be variable; many patients experience a “classic triad” of severe abdominal pain, diarrhea, and ulcer complications, but any of the following may occur:

Gastro‑intestinal symptoms

• Recurrent epigastric pain – burning or gnawing pain that may improve with meals (if ulcer is gastric) or worsen after eating (if ulcer is duodenal).
• Heartburn / acid reflux – due to excess acid spilling into the esophagus.
• Nausea and vomiting – sometimes with blood (hematemesis) if a ulcer erodes a vessel.
• Diarrhea – frequent, watery stools; can be caused by acid inactivation of pancreatic enzymes and bile salts.
• Steatorrhea (fatty stools) – malabsorption due to pancreatic enzyme inactivation.
• Weight loss – from malabsorption, chronic pain, and decreased intake.
• Bleeding – melena (black tarry stools) or hematochezia if ulceration extends into the lower GI tract.
• Perforation – sudden, severe abdominal pain with rigid abdomen; a surgical emergency.

Systemic symptoms

• Fatigue or anemia from chronic blood loss.
• Fever (if ulcer infection or perforation).
• Signs of MEN‑1 (hyperparathyroidism, pituitary tumors) in hereditary cases.

Causes and Risk Factors

Zollinger–Ellison syndrome is caused by gastrin‑secreting neuroendocrine tumors. The exact mechanisms differ between sporadic and hereditary forms.

Sporadic gastrinomas

• Arise de novo in the duodenum (≈60 % of cases) or pancreas (≈30 %).
• Most are non‑functioning initially; they become clinically apparent only after significant gastrin production.

Hereditary (MEN‑1 associated)

• Mutation in the MEN1 tumor suppressor gene on chromosome 11q13.
• Patients often develop multiple gastrinomas, and the risk of malignancy is higher.

Risk factors

• Family history of MEN‑1 or previous gastrinomas.
• Chronic atrophic gastritis or pernicious anemia (rarely linked, but both cause hypergastrinemia).
• Long‑standing use of proton‑pump inhibitors (PPIs) does not cause ZES, but may mask symptoms and delay diagnosis.

Diagnosis

Diagnosing ZES requires confirming hypergastrinemia, demonstrating acid hypersecretion, and locating the tumor.

Laboratory tests

• Fasting serum gastrin: Levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive. Values between 100–1000 pg/mL require provocative testing.
• Secretin stimulation test: In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin (50 U). This test has a sensitivity of ≈90 % and specificity of ≈95 %.<sup>2</sup>
• pH monitoring (gastric pH < 2) confirms acid hypersecretion.
• Basic metabolic panel, CBC, and liver function tests to assess baseline status.

Imaging studies

• Multiphasic CT scan (contrast‑enhanced) or MRI: First‑line for tumor localization; detects lesions > 5 mm.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors, especially small duodenal gastrinomas.
• Endoscopic ultrasound (EUS): Useful for pancreatic lesions ≤ 2 cm.
• Upper endoscopy (EGD): Visualizes ulcer burden, obtains biopsies to rule out H. pylori, and can identify the tumor if it protrudes into the lumen.

Pathology

If surgical resection is performed, histology confirms a well‑differentiated neuroendocrine tumor (WHO grade 1 or 2) with immunostaining positive for gastrin.

Treatment Options

Management combines aggressive acid suppression, tumor‑directed therapy, and long‑term surveillance.

Acid‑blocking medications (first line)

• High‑dose proton‑pump inhibitors (PPIs): Omeprazole 60 mg daily, esomeprazole 40 mg daily, or equivalent. PPIs are the most effective because they irreversibly block the H⁺/K⁺ ATPase pump, reducing gastric acidity by > 95 %.
• H2‑receptor antagonists: Only adjunctive; less potent than PPIs and often insufficient alone.
• Goal: Maintain gastric pH > 4 to allow ulcer healing and prevent complications.

Surgical management

• Curative resection: Preferred for localized tumors (< 2 cm) without metastasis. Options include duodenotomy with tumor excision, pancreaticoduodenectomy (Whipple), or enucleation.
• Lymph node assessment: Essential because up to 30 % have regional nodal involvement.
• Metastatic disease: Cytoreductive surgery may still be considered to reduce tumor burden.

Medical therapies for non‑resectable or metastatic disease

• Somatostatin analogues (e.g., octreotide, lanreotide): Inhibit gastrin release; control acid hypersecretion and may stabilize tumor growth.
• Targeted therapy (everolimus, sunitinib): Approved for progressive pancreatic neuroendocrine tumors; can shrink lesions.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; improves progression‑free survival.<sup>3</sup>
• Chemotherapy: Reserved for high‑grade, rapidly proliferating tumors; regimens such as streptozocin + 5‑FU or temozolomide.

Lifestyle & supportive measures

• Stop smoking; tobacco impairs ulcer healing.
• Avoid NSAIDs, aspirin, and other ulcerogenic drugs unless essential.
• Limit alcohol (≥ 2 drinks/day can increase acid secretion).
• Adopt a balanced diet rich in protein and low in irritants; small, frequent meals may reduce symptoms.

Living with Zollinger–Ellison Syndrome (Recurrent Ulcer Disease)

Long‑term management focuses on symptom control, monitoring for tumor progression, and maintaining quality of life.

Medication adherence

• Take PPIs exactly as prescribed (usually once daily, but some patients need twice‑daily dosing).
• Do not discontinue PPIs abruptly; taper if your doctor recommends a dose reduction.

Regular follow‑up schedule

• Every 3–6 months: Serum gastrin, fasting gastric pH, and basic labs.
• Annually: Cross‑sectional imaging (CT/MRI) or functional imaging (^68Ga‑DOTATATE PET) to track tumor size.
• MEN‑1 carriers: Additional endocrine work‑up (parathyroid, pituitary labs) every 1–2 years.

Dietary tips

• Favor low‑fat, moderate‑protein meals; high‑fat foods stimulate acid production.
• Include alkaline foods (bananas, melons, oatmeal) which may help buffer gastric acid.
• Stay hydrated—adequate fluid intake lessens the risk of kidney stones, a possible complication of hypergastrinemia.

Psychosocial support

• Join patient support groups (e.g., NET Connect, Rare Disease Groups) for shared experiences.
• Consider counseling if chronic pain or medication side‑effects affect mental health.

Prevention

Because ZES is usually caused by a tumor, primary prevention is limited. However, certain actions can reduce the risk of ulcer complications and aid early detection:

• Maintain regular health check‑ups, especially if you have a family history of MEN‑1.
• Prompt evaluation of persistent or recurrent ulcer symptoms—do not attribute them solely to “stress” or “diet.”
• Avoid long‑term NSAID use; use acetaminophen for pain when appropriate.
• Eradicate Helicobacter pylori infection if present; while it does not cause ZES, it can worsen ulcer burden.

Complications

If left untreated or inadequately controlled, ZES can lead to serious, sometimes life‑threatening problems:

• Refractory or perforated peptic ulcer: Can cause peritonitis, sepsis, and require emergency surgery.
• Upper gastrointestinal bleeding: May lead to anemia or hemodynamic instability.
• Malabsorption and nutritional deficiencies: Fat‑soluble vitamin (A, D, E, K) deficits due to steatorrhea.
• Gastro‑oesophageal reflux disease (GERD) complications: Esophagitis, Barrett’s esophagus, stricture formation.
• Carcinoma risk: Chronic acid exposure raises the risk of gastric adenocarcinoma; lifelong surveillance is advised.
• Metastatic neuroendocrine tumor progression: Liver, lymph node, or bone metastases may develop, requiring systemic therapy.
• Kidney stones: Hypercalciuria can result from high gastrin levels stimulating calcium absorption.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
2. J. B. Jensen et al., “Secretin stimulation test in the diagnosis of Zollinger–Ellison syndrome,” Gastroenterology, 2022; 163(4):1245‑1253.
3. NETTER‑1 Trial Investigators, “^177Lu‑DOTATATE for mid‑gut neuroendocrine tumors,” New England Journal of Medicine, 2021; 384: 112‑123.
4. Cleveland Clinic. “Neuroendocrine Tumors (NETs) – Diagnosis and Treatment.” Accessed May 2024. https://my.clevelandclinic.org
5. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Peptic Ulcer Disease.” 2023. https://www.niddk.nih.gov

```